OPKO Confirms Resumption of Common Stock Trading on Nasdaq
September 14 2018 - 1:33PM
Business Wire
OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The
Nasdaq Stock Market has lifted the trading suspension of OPKO’s
shares.
As noted previously, OPKO and 19 other defendants, including Dr.
Phillip Frost, its CEO and Chairman, were named in a Complaint
filed on September 7 by the Securities and Exchange Commission
(“SEC”). The Company will vigorously defend itself against these
charges.
As noted previously, the SEC’s lawsuit does not contain any
allegations about OPKO’s financial practices, financial statements
or business practices.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company. In diagnostics,
its BioReference Laboratories is the nation's third largest
clinical laboratory; GeneDx is a rapidly growing genetic testing
business; the 4Kscore® prostate cancer test is used to confirm an
elevated PSA to help decide about next steps such as prostate
biopsy; Claros® 1 is a point of care diagnostics platform with PSA
and testosterone as the most advanced in development. In our
pharmaceutical pipeline, RAYALDEE is our first pharmaceutical
product to be marketed. OPK88003, a once weekly oxyntomodulin for
type 2 diabetes and obesity in Phase 2 clinical trials, is among a
new class of GLP-1 glucagon receptor dual agonists. OPK88004, a
SARM (Selective Androgen Receptor Modulator) for treating BPH
(Benign Prostatic Hypertrophy), urinary incontinence and other
conditions is in clinical trials. The Company’s most advanced
product utilizing its CTP technology, a once-weekly human growth
hormone for injection, is in Phase 3 trials and is partnered with
Pfizer.
OPKO has research, development, production and distribution
facilities abroad. More information is available at
www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding the
outcome of the SEC lawsuit, as well as other non-historical
statements about our expectations, beliefs or intentions. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180914005471/en/
Sard Verbinnen & CoJamie Tully or Devin
Broda212-687-8080orLHA Investor RelationsMiriam Weber Miller,
212-838-3777MMiller@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024